Percutaneous or intradermal BCG vaccine?

Jornal de Pediatria

Volumn 80, Issue 2, 2004, Pages 93-98

  Bricks, Lucia F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adverse effects; BCG vaccine administration; Efficacy; Tuberculosis prevention and control

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; TUBERCULIN;

BCG VACCINATION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DATA BASE; DEATH; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; INJECTION SITE REACTION; INJECTION SITE SCAR; KELOID; LITERATURE; LYMPHADENITIS; LYMPHADENOPATHY; MEDLINE; MILIARY TUBERCULOSIS; NONHUMAN; REVIEW; SKIN ABSCESS; TH1 CELL; TH2 CELL; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOUS MENINGITIS; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; BCG VACCINE; HUMANS; IMMUNOLOGIC TESTS; INJECTIONS, INTRADERMAL; TUBERCULOSIS;

EID: 16544393058     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/1146     Document Type: Review

References (54)

1. Brewer TF. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin Infect Dis. 2000;31 Suppl 3:64-7.
2. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HY, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA. 1994;271: 698-702.
3. Fundação Nacional de Saúde [site na Internet]. Ministério da Saúde; c1999-2003 [citado em 16 de março de 2004] Disponível em: http://www.funasa.gov.br.
4. Glatthaar E, Kleberg HH. BCG immunization of infants by percutaneous multiple puncture. S Afr Med J. 1977;52:1173-4.
5. Lotte A, Wasz-Hockert W, Poisson N. Second IUATLD study on complications induced by intradermal BCG vaccination. Bull Int Union Tuberc Lung Dis. 1988;63:47-59.
6. Mori T, Yamauchi Y, Shiozawa K. Lymph node swelling due to bacille Calmette-GuErin vaccination with multipuncture method. Tubercle Lung Dis. 1996;77:269-73.
7. Research Committee of the British Thoracic and Tuberculosis Association. BCG vaccination by multiple-puncture: fourth report. Tubercle. 1971;52:19-30.
8. Vaughan JP, Menu JP, Lindqvist KJ, Vennema A. Percutaneous BCG immunization trial using WHO biffurcated needle. J Trop Med Hyg. 1973;76:143-6.
9. Canner EW. Percutaneous multiple puncture method of administering BCG vaccine. Public Health. 1991;105:405.
10. Chisholm CJ, Nair P. Route of administration of BCG in a school population: outcome of an audit of clinical practice in North Bedfordshire. Public Health. 1999;113:177-9.
11. Cundall DB, Ashelford DJ, Pearson SB. BCG immunization of infants by percutaneous multiple puncture. BMJ. 1988;297: 1173-4.
12. Jarad NA, Empey DW, Duckworth G. Administration of the BCG vaccination using the multipuncture method in school children: a comparison with intradermal method. Thorax. 1999;54:762-4.
13. Ormerod LP, Garnett JM. Tuberculin response after neonatal BCG vaccination. Arch Dis Child. 1988;63:1491-2.
14. Ormerod LP, Palmer C Tuberculin reactivity after neonatal percutaneous BCG immunization. Arch Dis Child. 1993;69:155.
15. Rahman M, Sekimoto M, Takamatsu I, Hira K, Shimbo T, Toyoshima K, et al. Economic evaluation of universal BCG vaccination of Japanese infants. Int J Epidemiol. 2001;302:380-5.
16. Trnka L, Dankova D, Zitova J, Cimprichova L, Migliori GB, Clancy L, et al. Survey of BCG vaccination policy in Europe: 1994-96. Bull World Health Organ. 1998;76:85-91.
17. São Paulo. Centro de Vigilância Epidemiológica Prof. Alexandre Vranjac. Comissão Permanente de Assessoramento em Imunizações. Secretaria de Estado de Saúde. São Paulo. Norma Técnica do Programa de Imunização, 1998. São Paulo: De Paula Print Artes Gráficas; 1998. 51p.
18. Caldeira Reis, FJ. Alergia tuberculínica e cicatriz vacinal em lactentes que tomaram a vacina BCG injetável quando recém-nascidos. J Pediatr (Rio J). 1982;52:23-8.
19. Jeena PM, Chhagan MK, Topley J, Coovadia HM. Safety of the intradermal Copenhagen 1331 BCG vaccine in neonates in Durban, South Africa. Bull World Health Organ. 2001;179:337-43.
20. Amato Neto V, Finger H. Avaliação, por meio do teste tuberculínico realizado precocemente, da efetividade de imunização com vacina BCG administrada pela via intradérmica a crianças sadias com no máximo 3 meses de díade, residentes na cidade de São Paulo. Rev Goiana Med. 1976;22:87-90.
21. Arantes G. Sensibilidade tuberculínica pós-vacinal e sua irrelevância para revacinação BCG. Rev Saude Publica (S. Paulo). 1980;14:234-45.
22. Oliveira CF, Farhat CK. BCG-teste em crianças sadias previamente vacinadas coma BCG Moreaux-Rio de Janeiro. J Pediatr (Rio J). 1994;70:344-50.
23. Sarinho ESC, Aguiar Filho, AS, Silva AMR. Pode-se utilizar o teste de Mantoux em crianças vacinadas com BCG? J Pediatr (Rio J). 1994;70:91-4.
24. Pereira SM, Dourado I, Barreto ML, Cunha SS, Ichiara MY, Hijjar MA, et al. Sensitivity and specificity of BCG scar reading in Brazil. Int J Tuberc Lung Dis. 2001;11:1067-70.
25. Ferreira AA, Bunn-Moreno MM, Sant'Anna CC, Ferreira MFC. BCG vaccination in low birth weight newborns: analysis of lymphocyte proliferation, IL-2 generation and intradermal reaction to PPD. Tubercle Lung Dis. 1996;77:476-81.
26. Ferreira AA, Ferreira MFC, Macedo EA, Cunha I, Santos SL, Reis AR, et al. Revacinação BCG em escolares: evolução da lesão vacinal entre 48 horas e 10 semanas. J Pediatr (Rio J). 2002;78: 289-94.
27. Floyd S, Ponnighaus JM, Bliss L, Wardorff DK, Kasunga A, Mogha P, et al. BCG scars in northern Malawi: sensitivity and repeatability of scar reading, and factors affecting scar size. Int J Tuberc Lung Dis. 2000;12:1133-42.
28. Kuyucu N, Kuyucu S, Bakirtas A, Karacan C. BCG revaccination and tuberculin reactivity. Indian J Pediatr. 2001;68:21-5.
29. Fjallbrant H, Ridell M, Larson LO. The tuberculin skin test in reaction to immunological in vitro reactions in BCG-vaccinated healthcare workers. Eur Respir J. 2001;18:376-80.
30. Miles MM, Shaw RJ. Effect of inadvertent intradermal administration of high doses percutaneous BCG vaccine. BMJ. 1996;312:1205.
31. Fine PEM, Sterne JAC, Ponnighaus JM, Rees RJW. Delayed-type hypersensitivity, mycobacterial vaccines and protective immunity. Lancet. 1994;344:1245-9.
32. Fine PEM. Variation in protection by BCG implications of and for heterologous immunity. Lancet. 1995;346:1339-91.
33. Fine PEM. BCG: The challenge continues. Scand J Infect Dis. 2001;33:243-5.
34. Tala-Heikkika MM, Tuominen JE, Tala EOJ. Bacillus Calmette-Guérin revaccination questionable with low tuberculosis incidence. Am J Respir Crit Care Med. 1998;157:1324-7.
35. Awasthi S, Moin S. Effectiveness of BCG vaccination against tuberculous meningitis. Indian Pediatr. 1999;36:455-60.
36. Fifteen year follow up trial of BCG vaccines in south India for tuberculosis prevention. Tuberculosis Research Centre (ICMR), Chennai. Indian J Med Res. 1999;110:56-69.
37. Al-Kassimi FA, Al-Hajjaj MMS, A-ORainey IO, Bamgboye EA. Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction? Am J Crit Care Med. 1995;152:1575-8.
38. Black GF, Weir RE, Floyd S, Biss L, Warndorff DK, Cramping AC, et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomized controlled studies. Lancet. 2002;359(9315):1393-1401.
39. Brandt L, Cunha JF, Olsen AW, Chilima B, Hirsch P, Appelberg R, et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun. 2002;70:672-8.
40. Kemp EB, Belshe RB, Hoft DF. Immune responses stimulated by percutaneous and intradermal Bacille Calmette-Guerin. J Infect Dis. 1996;174:113-19.
41. Leung CC, Tam CM, Chan SL, Chan-Yeung M, Chan CK, Chang KC. Efficacy of BCG revaccination program in a cohort given BCG vaccination at birth in Hong Kong. Int Tuberc Lung Dis. 2001;5:717-23.
42. Lowry PW, Ludwig TS, Adams JA, Fitzpatrick ML, Grant SM, Andre GA, et al. Cellular immune responses to four doses of percutaneous Bacille Calmette-Guérin in healthy adults. J Infect Dis. 1998;178:138-46.
43. Ravn P, Boesen H, Pedersen BK, Andersen P. Human T cell responses induced by vaccination with Mycobacterium bovis Bacillus Calmette-Guerin. J Immunol. 1999;158:1949-55.
44. Schuluger NW, Rom WN. The host immune response to tuberculosis. Am J Respir Crit Care Med. 1998;157:679-91.
45. Pouchot J, Grasland A, Collet C, Coste J, Esdaile J, Vinceneux P. Reability of tuberculin skin test measurement. Ann Intern Med. 1997;126:210-14.
46. Hoft DF, Tennant JM. Persistence and boosting of bacille Calmette-Guerin-induced delayed-type hypersensitivity. Ann Intern Med. 1999;131:32-6.
47. Ellner JJ, Hirsch CS, Whalen CC. Correlates of protective immunity to Mycobacterium tuberculosis in humans. Clin Infect Dis. 2000;30 Suppl 3:279-282.
48. Seah GT, Scott GM, Rook GAW. Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis. J Infect Dis. 2000;181:385-9.
49. Hussey GD, Watkins ML, Goddard EA, Gottschalk S, Hughes EJ, Iloni K, et al. Neonatal mycobacterial specific cytotoxic T-lymphocyte and cytokine profiles in response to distinct BCG vaccination strategies. Immunology. 2002;105:314-24.
50. Marchant A, Goetghebuer T, Ota MO, Wolfe I, Ceesay SJ, Groote D, et al. Newborns develop a Th1-type immune response to Mycobacterium bovis Bacillus Camette-Guerin vaccination. J Immunol. 1999;163:2249-55.
51. Skucce RA, Neill SC. Molecular epidemiology of Mycobacterium bovis: exploring molecular data. Tuberculosis (Edinb). 2001;81:169-75.
52. Snider DE Jr. Ethical issues in tuberculosis vaccine trials. Clin Infect Dis. 2000;30 Suppl 3:271-5.
53. Choi IS, Koh UI. Therapeutic effects of BCG vaccination in adult asthmatic patients: a randomized, controlled trial. Ann Allergy Asthma Immunol. 2002;88:584-91.
54. von Reyn CF, Vuola JM. New vaccines for the prevention of tuberculosis. Clin Infect Dis. 2002;35:465-74.